159 results
8-K
EX-99.1
DRRX
Durect Corp
30 Apr 24
Other Events
2:30pm
death and survival, and lipid biosynthesis. This may ultimately lead to improved cell survival, reduced inflammation, and decreased lipotoxicity
8-K
EX-99.1
DRRX
Durect Corp
27 Mar 24
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4:15pm
modulates expression of genes that are involved in cell signaling pathways associated with stress responses, cell death and survival, and lipid
8-K
EX-99.1
DRRX
Durect Corp
13 Nov 23
DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update
4:15pm
modulates expression of genes that are involved in cell signaling pathways associated with stress responses, cell death and survival, and lipid
8-K
EX-99.1
8ljvg
7 Nov 23
DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial
4:10pm
8-K
EX-99.2
fmq9f392m2cynyxekjox
7 Nov 23
DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial
4:10pm
8-K
EX-99.1
ugs5p
7 Sep 23
DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial
9:02am
8-K
EX-99.1
k4rq3cr2
9 Aug 23
DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update
4:23pm
424B5
bpozulyi25ep2rlcj4cf
21 Jul 23
Prospectus supplement for primary offering
10:38am
8-K
EX-10.1
ei5o3prlncdiq24d oo
22 Jun 23
Departure of Directors or Certain Officers
4:30pm
8-K
EX-99.1
exlwzw
7 Jun 23
DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis
9:00am
8-K
EX-99.1
jzmasgovnmcp4yma
16 May 23
Regulation FD Disclosure
12:08pm
8-K
EX-99.1
cecgc8
8 May 23
DURECT Corporation Reports First Quarter 2023 Financial Results and Business Update
4:15pm
8-K
EX-99.1
rqsjcyd
10 Apr 23
Company on track to report data from ongoing Phase 2b AHFIRM trial in 2H 2023
9:30am
8-K
EX-99.1
4cr5 zg3b541
2 Nov 22
DURECT Corporation Reports Third Quarter 2022 Financial Results and Update of Programs
4:16pm